CytoMed Therapeutics Limited GDTC 深 滬
交易中 10-30 10:23:25 美东时间
2.295
+0.115
+5.28%
華盛通- 最 高2.30
- 今 開2.14
- 成交量 5110股
- 最 低 2.1302
- 昨 收 2.18
- 總市值 2692.88万
- 52周最高 4.0499
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.65
- 委 比 15.94%
- 總股本 1173.37万
- 歷史最高 9.25
- 量 比 1.23
- 振 幅 7.79%
- 歷史最低 1.20
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CytoMed Therapeutics’ chairman increases effective holdings to 21.95%
CytoMed Therapeutics (NASDAQ:GDTC) said on Wednesday that its executive chairman and substantial shareholder, Peter Choo, has increased his shareholding in the company through recent open-market purch...
10-22 20:46
CytoMed Therapeutics Submits Cash Bid To Acquire TC BioPharm; Terms Not Disclosed
SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary
10-14 20:04
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
CytoMed Therapeutics Limited has submitted a cash bid to acquire certain assets of TC BioPharm Limited (TCBL), another clinical-stage biopharmaceutical company focused on donor-derived allogeneic gamma delta T cells for cancer treatment. The proposed acquisition aims to enhance CytoMed’s expertise in cell therapies, accelerate commercialization, and provide affordable treatment options for cancer patients globally. TCBL has completed a Phase I cl...
10-14 12:00
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
CytoMed Therapeutics, a Singapore-based biopharmaceutical company, announced the publication of a preclinical study in collaboration with MD Anderson Cancer Center, highlighting the potential of its allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). The study suggests promising results for further clinical development, with plans to advance the therapy into clinical trials in Southeast Asia. CytoMed, spun off from A...
10-02 11:00
CytoMed Therapeutics Reports Increased Revenue Amidst Financial Challenges
The latest announcement is out from CytoMed Therapeutics Limited ( ($GDTC) ). O...
09-30 19:29
Grayscale® Near Trust Now Trading on OTCQB® Market
Grayscale® Near Trust (GSNR) begins trading on OTCQB, enabling wider access to the NEAR blockchain platform tailored for AI applications. Near's "intents" simplify cross-chain transactions, enhancing mainstream adoption. Grayscale highlights its role in advancing digital asset investing through institutional-grade products, reflecting its commitment to on-chain innovation.
09-26 13:00
CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived
08-28 21:07
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
CytoMed Therapeutics has successfully expanded clinical-scale NK cells from cryopreserved cord blood units, enabling the creation of a new business platform. The company is reorganizing to establish LongevityBank, focusing on autologous therapies, while CytoMed continues developing allogeneic therapies with ongoing clinical trials. The acquisition of a licensed cord blood bank in Malaysia provides access to valuable cord blood for therapeutic dev...
08-28 13:00
CytoMed Therapeutics plans to raise ~$4.3M via ATM offering
Clinical-stage biopharmaceutical company CytoMed Therapeutics (NASDAQ:GDTC) entered into an at-the-market sales agreement with R.F. Lafferty & Co., as the sales agent. The company may offer and sell...
08-19 14:06
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
CytoMed Therapeutics entered into an At-the-Market Sales Agreement with R.F. Lafferty & Co., Inc., allowing the company to sell up to $4.3 million worth of ordinary shares. Proceeds will be used for general corporate purposes, including business diversification, development initiatives, and potential acquisitions or strategic investments. The company has seen 2,500 new customer sign-ups at its newly acquired cord blood bank since August 2024.
08-19 01:00
